On Friday, July 28, 2017, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) supported, by a vote of 12-Yes to 1-No, with 3 abstentions, the safety of Heplisav-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] by Dynavax Technologies Corporation (Dynavax) when administered to adults aged 18 years and older. The FDA’s goal date to decide on whether to approve Heplisav-B is August 10, 2017.
Back to All Events
Earlier Event: July 26Anesthetic and Analgesic Drugs Advisory Committee and Drug Safety and Risk Managment Advisory Committee
Later Event: August 2Arthritis Advisory Committee